Lupin arm acquires right to Limbitrol, Bacrocin and 7 other medicines from Bausch Health
Mumbai: Global pharma major, Lupin Limited has announced that the company's wholly-owned subsidiary in Brazil, MedQuímica Indústria Farmacêutica, has signed a definitive agreement to acquire all rights to nine medicines from BL Indústria Ótica Ltda., a subsidiary of Bausch Health Companies Inc.
As part of the transaction, MedQuímica will acquire rights to nine products including Limbitrol, Melleril, and Dalmadorm for Central Nervous System related conditions, Bacrocin, Glyquin, Solaquin, Oxipelle and Efurix as topical oncological treatments, and Cuprimine for the treatment of Wilson's disease.
"This move reinforces our commitment to making healthcare solutions accessible to all patients," the release stated.
"The acquired brands are well established and recognized among doctors and other members of the medical fraternity in Brazil for their reliability, safety, and trustworthiness," said Alexandre Franca, Managing Director, MedQuímica. "This transaction enhances our product portfolio in Brazil and strengthens our position in the prescription market."
Read also: Lupin CSR arm, Rajasthan Govt join hands to strengthen Healthcare system
MedQuímica Pharmaceutical Industries, with its factory located in the Industrial District of Juiz de Fora, has been operating for 47 years. In 2015 it became part of the Lupin Group. In Brazil, Medquímica develops an extensive line of both solid and liquid medicines classified into five lines: OTC (Over the counter medicines), Branded Generics, Hospital, Generics, and Food Supplements.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle-East regions.
The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women's health areas. The company invested 8.7% of its revenue in research and development in FY22.
